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Background
Treatment of hepatitis C virus (HCV) in HCV/HIV co-
infected patients requires the simultaneous management
of two complex regimens, including addressing potential
drug interactions between HCV and HIV medications.
Methods
TEN-SWITCH is a prospective, observational study to
evaluate the impact of substituting tenofovir (TDF) for
other nucleoside analogues in virologically controlled
HIV-infected patients (HIV RNA <400 copies/mL) on
maintenance of virologic suppression and immune status
in HCV/HIV co-infected subjects. Adverse events and HCV
treatment uptake following a switch to TDF were also
evaluated.
Summary of results
Among 23 subjects enrolled (mean age 45 years, 83%
male), 44% were HCV genotype 3, 65% were receiving
methadone and 87% reported a history of illicit and injec-
tion drug use. The median number of previous NRTIs,
NNRTIs and PIs were 2 (range: 0–4), 1 (range: 0–2) and 0
(range: 0–4), respectively. Prior to switch, subjects
received PI- (n = 18, LPV/RTV = 9, IDV/RTV = 1, SQV/RTV
= 1, ATV/RTV = 2, ATV = 4) or NNRTI-based (n = 5, EFV =
2, NVP = 3, DLV = 1) HAART in combination with either
3TC/DDI (n = 14), ABC/DDI (n = 2), FTC/DDI (n = 1),
3TC/d4T (n = 4), 3TC/AZT (n = 1) or ABC/AZT (n = 1).
Median baseline CD4+ count and HIV RNA were 350
(range: 40–999) cells/mm3 and <50 (range: 0–75) copies/
mL. Overall, 100% and 91% had HIV-RNA <400 copies/
mL and <50 copies/mL, respectively. Among the 18 sub-
jects having completed 12 months of follow-up, two sub-
jects (11%) discontinued TDF following a switch (one
due to adverse events, nausea and vomiting likely associ-
ated with addition of RTV to unboosted ATV regimen; one
due to non-adherence). Two other adverse events that did
not require therapy discontinuation were observed (one –
vertigo, one – nausea with the addition of RTV). At 12
months of follow-up, the median CD4+ count and HIV-
RNA were 530 (range: 180–999) cells/mm3 and <50
(range: 0–82) copies/mL. At 12 months (intent to treat),
89% and 83% had HIV-RNA <400 copies/mL and <50
copies/mL, respectively. Of 18 subjects, three (17%) initi-
ated treatment for HCV infection.
Conclusion
Switching nucleosides in an effective HAART regimen to
TDF in preparation for HCV treatment to address poten-
tial ribavirin/nucleoside interactions is a safe intervention
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